Hikma Pharmaceuticals PLC
H5P
Company Profile
Business description
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
Contact
10 Portman Square
LondonW1H 6AZ
GBRT: +44 2073992760
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
9,603
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 6.40 | 0.07% |
| CAC 40 | 8,370.50 | 37.63 | 0.45% |
| DAX 40 | 26,793.64 | 130.87 | 0.49% |
| Dow JONES (US) | 52,627.21 | 140.72 | 0.27% |
| FTSE 100 | 10,863.42 | 27.95 | 0.26% |
| HKSE | 24,008.55 | 307.37 | -1.26% |
| NASDAQ | 25,455.70 | 10.49 | -0.04% |
| Nikkei 225 | 60,819.36 | 359.78 | 0.60% |
| NZX 50 Index | 14,259.23 | 91.82 | 0.65% |
| S&P 500 | 7,624.76 | 5.38 | 0.07% |
| S&P/ASX 200 | 9,146.80 | 17.80 | 0.19% |
| SSE Composite Index | 3,655.83 | 24.81 | -0.67% |